SynthesisNature communications2014
A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus.
Open access · bronzeAbstract readMeta-Analysis
In one paragraph
Synthesis in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 5 pooled it
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Association of Single-Nucleotide Variants in the Human Leukocyte Antigen and Other Loci With Childhood Hodgkin Lymphoma.JAMA network open · 2022Pooled it
- Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.Blood · 2018Pooled it
- Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.Nature communications · 2017Pooled it
- Candidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis.Hematological oncology · 2017Pooled it
- Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis.International journal of epidemiology · 2016Pooled it
- Integration of transcriptome-wide association study and gene-based association analysis identifies candidate genes for Hodgkin lymphoma.Journal of cancer research and clinical oncology · 2025Article
- Time and space co-ordinates of Hodgkin's lymphoma in Sardinia, Italy.Journal of the National Cancer Center · 2025Article
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
- Germline genetic regulation of the colorectal tumor immune microenvironment.BMC genomics · 2024Article
- Altered Transcriptome Response in PBMCs of Czech Adults Linked to Multiple PFAS Exposure: B Cell Development as a Target of PFAS Immunotoxicity.Environmental science & technology · 2024Article
- Deciphering the Genetic Complexity of Classical Hodgkin Lymphoma: Insights and Effective Strategies.Current genomics · 2024Review
- A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.Blood advances · 2023Article
- Review
- Improve the model of disease subtype heterogeneity by leveraging external summary data.PLoS computational biology · 2023Article
- Identification and Interpretation of eQTL and eGenes for Hodgkin Lymphoma Susceptibility.Genes · 2023Article
- Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma.Blood · 2023Article
- Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.Leukemia · 2022Article
- Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma.Journal of clinical medicine · 2022Review
- Article
- Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
67 authors at 20 institutions in 14 countries.
W Cozen1] USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA [2].
M N Timofeeva1] International Agency for Research on Cancer (IARC), 69372 Lyon, France [2] Institute of Genetics and Molecular Medicine, University of Edinburgh, EH4 2XU Edinburgh, UK [3].
D Li1] [2].
A Diepstra1] University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands [2].
D Hazelett1] USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA [2].
M Delahaye-Sourdeix1] International Agency for Research on Cancer (IARC), 69372 Lyon, France [2].
C K EdlundUSC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA.
L FrankeUniversity of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands.
K RostgaardStatens Serum Institut, DK-2300 Copenhagen, Denmark.
D J Van Den BergUSC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA.
V K CortessisUSC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA.
K E SmedbyKarolinska Institutet and Karolinska University Hospital, S-221 00 Stockholm, Sweden.
S L GlaserCancer Prevention Institute of California, Fremont, California 94538, USA.
H-J WestraUniversity of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands.
L L RobisonSt Jude Children's Hospital, Cordova, Tennessee 38105, USA.
T M MackUSC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA.
H GhesquieresCentre Léon Bérard, UMR CNRS 5239-Université Lyon 1, 69008 Lyon, France.
A E HwangUSC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA.
A NietersUniversity Medical Centre Freiburg, D-79085 Freiburg, Germany.
S de SanjoseIDIBELL Institut Català d'Oncologia, 8907 Barcelona, Spain.
T LightfootUniversity of York, YO10 5DD York, UK.
N BeckerGerman Cancer Research Centre, D-69120 Heidelberg, Germany.
M MaynadieCHU de Dijon, EA 4184, University of Burgundy, 21070 Dijon, France.
L ForetovaMasaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
E RomanUniversity of York, YO10 5DD York, UK.
Y BenaventeIDIBELL Institut Català d'Oncologia, 8907 Barcelona, Spain.
K A RandUSC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA.
B N NathwaniCity of Hope National Medical Center, Duarte, California 91010, USA.
B GlimeliusUppsala University, 75285 Uppsala, Sweden.
A StainesSchool of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland.
P BoffettaIcahn School of Medicine at Mount Sinai, New York City, New York 10029-6574, USA.
B K LinkUniversity of Iowa College of Medicine, Iowa City, Iowa 52242, USA.
L KiemeneyRadboud University Nijmegen Medical Centre, 6500HB Nijmegen, The Netherlands.
S M AnsellMayo Clinic, Rochester, Minnesota 55905, USA.
S BhatiaCity of Hope National Medical Center, Duarte, California 91010, USA.
L C StrongMD Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA.
P GalanINSERM U557 (UMR Inserm; INRA; CNAM, Université Paris 13), 93017 Paris, France.
L VattenNorwegian University of Science and Technology, NO-7491 Trondheim, Norway.
T M HabermannMayo Clinic, Rochester, Minnesota 55905, USA.
E J DuellIDIBELL Institut Català d'Oncologia, 8907 Barcelona, Spain.
A LakeMRC University of Glasgow Centre for Virus Research, Garscube Estate, University of Glasgow, G12 8QQ Glasgow, Scotland, UK.
R N VeenstraUniversity of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands.
L VisserUniversity of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands.
Y LiuUniversity of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands.
K Y UrayamaDepartment of Human Genetics and Disease Diversity, Tokyo Medical and Dental University, Tokyo 104-0044, Japan.
D MontgomeryMRC University of Glasgow Centre for Virus Research, Garscube Estate, University of Glasgow, G12 8QQ Glasgow, Scotland, UK.
V GaborieauInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
L M WeissClarient Pathology Services, Aliso Viejo, California 92656, USA.
G ByrnesInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
M LathropGenome Quebec, Montreal, Canada H3A 0G1.
P CoccoInstitute of Occupational Health, University of Cagliari, Monserrato, 09042 Cagliari, Italy.
T BestThe University of Chicago, Chicago, Illinois 60637-5415, USA.
A D SkolThe University of Chicago, Chicago, Illinois 60637-5415, USA.
H-O Adami1] Karolinska Institutet and Karolinska University Hospital, S-221 00 Stockholm, Sweden [2] Harvard University School of Public Health, Boston, Massachusetts 02115, USA.
M MelbyeStatens Serum Institut, DK-2300 Copenhagen, Denmark.
J R CerhanMayo Clinic, Rochester, Minnesota 55905, USA.
A GallagherMRC University of Glasgow Centre for Virus Research, Garscube Estate, University of Glasgow, G12 8QQ Glasgow, Scotland, UK.
G M TaylorSchool of Cancer Sciences, University of Manchester, St Mary's Hospital, M13 0JH Manchester, UK.
S L SlagerMayo Clinic, Rochester, Minnesota 55905, USA.
P BrennanInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
G A CoetzeeUSC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA.
D V ContiUSC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA.
K Onel1] The University of Chicago, Chicago, Illinois 60637-5415, USA [2].
R F Jarrett1] MRC University of Glasgow Centre for Virus Research, Garscube Estate, University of Glasgow, G12 8QQ Glasgow, Scotland, UK [2].
H Hjalgrim1] Statens Serum Institut, DK-2300 Copenhagen, Denmark [2].
A van den Berg1] University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands [2].
J D McKay1] International Agency for Research on Cancer (IARC), 69372 Lyon, France [2].
University of Southern California · USUniversity Medical Center Groningen · NLCentre International de Recherche sur le Cancer · FRInstitut d'Investigació Biomédica de Bellvitge · ESMayo Clinic · USUniversity of Chicago · USUniversity of Glasgow · GBCity Of Hope National Medical Center · USInstitut de Recherche Vaccinale · FRUniversity of York · GBCancer Prevention Institute of California · USCedars-Sinai Medical Center · USCentre de Recherche Épidémiologie et StatistiqueCentre Hospitalier Universitaire Dijon Bourgogne · FRDublin City University · IEGénome QuébecGerman Cancer Research Center · DEHarvard University Press · USIcahn School of Medicine at Mount Sinai · USKarolinska Institutet · SE
Funding
Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7MThe Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7MCALIFORNIA'S PARTICIPATION IN THE NATIONAL CANCER PREVENTION AND CONTRO PROGRAMU58DP000807 · DP · PUBLIC HEALTH INSTITUTE · PI SNIPES, KURT P · 2007 to 2011
$22.5MUCCRC--ETIOLOGY OF TREATMENT-INDUCED SECONDARY LEUKEMIAP01CA040046 · NCI · UNIVERSITY OF CHICAGO · PI LARSON, RICHARD A · 1985 to 2012
$19.9MMolecular Epidemiology of NHL and CLLR01CA092153 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R · 2003 to 2012
$6.7MProstate Cancer Risk EnhancersR01CA136924 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COETZEE, GERHARD A, FARNHAM, PEGGY J · 2010 to 2019
$5.4MDETERMINANTS OF THE SECULAR INCREASE IN NHLR01CA069269 · NCI · STATENS SERUM INSTITUT · PI MELBYE, MADS · 1998 to 2000
$644kPrognostic Genetic Biomarkers for CancerR21CA129045 · NCI · UNIVERSITY OF CHICAGO · PI ONEL, KENAN · 2007 to 2008
$338kCytokine Polymorphisms and Hodgkin Lymphoma RiskR03CA110836 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COZEN, WENDY · 2005 to 2006
$161kCHILDHOOD CANCER SURVIVOR STUDYU01CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ROBISON, LESLIE L · 1993 to 1999
–EPIDEMIOLOGY OF HD IN TWINS--INFECTIONS/T-CELL FUNCTIONR01CA058839 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACK, THOMAS MCCULLOCH · 1995 to 1997
–NCCDPHP CDC HHS 1U58DP000807-01NCCDPHP CDC HHS U58 DP000807NCI NIH HHS CA092153NCI NIH HHS CA097274NCI NIH HHS CA129045NCI NIH HHS CA40046NCI NIH HHS CA55727NCI NIH HHS N01 PC035139NCI NIH HHS N01-PC-35136NCI NIH HHS N01-PC-35139NCI NIH HHS P01 CA040046NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA092153NCI NIH HHS R01 CA136924NCI NIH HHS R01CA136924NCI NIH HHS R01CA58839NCI NIH HHS R01CA69269NCI NIH HHS R03 CA110836NCI NIH HHS R03CA110836NCI NIH HHS R21 CA129045NCI NIH HHS U24 CA055727NICHD NIH HHS HD0433871World Health Organization 001
Abstract
Recent genome-wide association studies (GWAS) of Hodgkin lymphoma (HL) have identified associations with genetic variation at both HLA and non-HLA loci; however, much of heritable HL susceptibility remains unexplained. Here we perform a meta-analysis of three HL GWAS totaling 1,816 cases and 7,877 controls followed by replication in an independent set of 1,281 cases and 3,218 controls to find novel risk loci. We identify a novel variant at 19p13.3 associated with HL (rs1860661; odds ratio (OR)=0.81, 95% confidence interval (95% CI) = 0.76-0.86, P(combined) = 3.5 × 10(-10)), located in intron 2 of TCF3 (also known as E2A), a regulator of B- and T-cell lineage commitment known to be involved in HL pathogenesis. This meta-analysis also notes associations between previously published loci at 2p16, 5q31, 6p31, 8q24 and 10p14 and HL subtypes. We conclude that our data suggest a link between the 19p13.3 locus, including TCF3, and HL risk.
Indexed as
Genetic Predisposition to DiseaseAdolescentAdultAgedAged, 80 and overBasic Helix-Loop-Helix ProteinsCase-Control StudiesChromosomes, Human, Pair 19Genetic VariationGenome-Wide Association StudyHodgkin DiseaseHumansMaleMiddle AgedYoung AdultBasic Helix-Loop-Helix ProteinsTCF3 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.